Ocular Therapeutix

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Ocular Therapeutix 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About OCUL

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. 

CEO
Pravin U. Dugel
CEOPravin U. Dugel
Employees
325
Employees325
Headquarters
Bedford, Massachusetts
HeadquartersBedford, Massachusetts
Founded
2006
Founded2006
Employees
325
Employees325

OCUL Key Statistics

Market cap
2.10B
Market cap2.10B
Price-Earnings ratio
-6.50
Price-Earnings ratio-6.50
Dividend yield
Dividend yield
Average volume
2.13M
Average volume2.13M
High today
$9.28
High today$9.28
Low today
$8.80
Low today$8.80
Open price
$8.80
Open price$8.80
Volume
2.01M
Volume2.01M
52 Week high
$16.44
52 Week high$16.44
52 Week low
$6.23
52 Week low$6.23

Stock Snapshot

With a market cap of 2.1B, Ocular Therapeutix(OCUL) trades at $9.28. The stock has a price-to-earnings ratio of -6.50.

On 2026-08-09, Ocular Therapeutix(OCUL) stock moved within a range of $8.80 to $9.28. With shares now at $9.28, the stock is trading +5.5% above its intraday low and 0.0% below the session's peak.

Trading volume for Ocular Therapeutix(OCUL) stock has reached 2.01M, versus its average volume of 2.13M.

The stock's 52-week range extends from a low of $6.23 to a high of $16.44.

The stock's 52-week range extends from a low of $6.23 to a high of $16.44.

OCUL News

Simply Wall St 2d
Does Ocular Therapeutix Pairing Flat Revenue With a New Shelf Point to a Shifting Funding Strategy?

In early August 2026, Ocular Therapeutix reported second-quarter 2026 results showing revenue of US$13.48 million, essentially flat year on year, while net loss...

Does Ocular Therapeutix Pairing Flat Revenue With a New Shelf Point to a Shifting Funding Strategy?
TipRanks 6d
Ocular Therapeutix reports Q2 EPS (35c), consensus (39c)

Reports Q2 revenue $13.48M, consensus $13.2M. “We continue to execute with discipline, precision, and urgency to redefine the retina experience and make AXPAXLI...

Analyst ratings

100%

of 12 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own OCUL. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.